Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

<p>A Phase III study will determine whether a long-acting form of an anti-HIV drug injected once every eight weeks can safely protect people from HIV infection at least as well as a combination of anti-HIV medications taken daily as an oral tablet.</p>

New Injectable Focus of HIV PrEP Clinical Trial